Логин: Пароль: ?
 
Продукты питания Ткань, одежда, обувь, постельное белье, текстиль Строительные материалы Бумага, пластик, промтовары Биотопливо Продукция для сельского хозяйства, зоотовары Косметика, средства гигиены Медицинские товары и препараты, лекарства Иное

 

Наши партнеры:

 

Новости/Аналитика

An experiment on the use of hemp for medical purposes in France in 2020 will not be implemented

23.06.2020

In particular, it depends on the Ukrainian public whether we will follow the scenario in this matter already implemented in Latin American countries where there is an unprecedented dominance of international hemp companies, mainly headquartered in Canada, or we will do as this policy is implemented in Holland, Israel, Uruguay , Australia, Great Britain, USA - when the conditions created by government officials allow the national producer to develop and he in an extremely short time not only fills the domestic market with high-quality and cheap products, but also creates capacities for the export of hemp raw materials or final products with high added value. 

The pages of the profile electronic publication of Ukrainian hemp breeders have repeatedly raised the question that " France is on the verge of launching a trial medical program to use the therapeutic properties of hemp ." The attention of our esteemed readers was focused on the preparations for the " Two-year French experiment to study the therapeutic properties of technical hemp ", described " How and why the French lobby for the creation of therapeutic hemp varieties of therapeutic orientation ." Given the fact that “ France is still the leader in European hemp breeding”, And the policy of the Gauls in this area of ​​management is of great importance in the pan-European market, experts at the Hemp Consulting information and analytical platform monitor trends related to competitors of the Fifth Republic. That is why the editorial office was asked to give a brief description of the situation on the market for services related to the use of hemp plants for medical purposes in the country of Cézana and Parmesan.

The economic crisis raging in the country became the basis for the adoption by the National Assembly of France of an amendment to the article of the law providing for experiments related to the use of hemp for medical purposes. In particular, the above short story is worded as follows: “With the exception of experiments related to the medical use of hemp, as provided for in Section 43 of Law No. 1446 of December 24, 2019 on Social Security Financing for 2020.”

Amendment text posted on the official website of the French National Assembly

Created by the National Agency for the Safety of Medicinal Products and Medical Devices (Agence nationale de sécurité du médicament et des produits de santé, ANSM), the Interim Scientific Committee (Comité Scientifique Temporaire) for two years was to study the effect of therapeutic properties of hemp on 3000 patients. The main goal of the research was to establish a system of patients' access to hemp leaves and inflorescences or preparations made on the basis of the therapeutic properties of the plant - prescription, dosage, staff training, delivery mechanism, etc. 

The project itself should stretch for 24 months and will be divided into 4 stages (6 months each):

- implementation;

- integration of patients into the project;

- monitoring the results of using the therapeutic properties of hemp;

- analysis of the data.

Only after the completion of all the above steps, the experts of the Interim Scientific Committee should prepare documents that will form the basis of the amendments to the current legislation of France. 

Commentary by the Ukrainian Technical Hemp Association

The experiment originally planned for implementation in September 2019 and postponed to January 2020 for the use of hemp for medical purposes in France is most likely to be delayed until 2021. A significant number of currently unresolved issues related to the practical work of the experts of the Interim Scientific Committee aimed at implementing the planned experiments, including those related to the lack of adequate funding, trained medical personnel, and in-house production, suggests that the implementation of the project to study the possibility of using the therapeutic properties of hemp in country will be delayed. Naturally, potential patients are outraged, and their arguments are consonant with those that are raised in support of Ukrainian bills being prepared on this topic. 

However, a significant difference between the European legal culture of the adoption of relevant regulatory legal acts is the justification for the need to amend the existing regulatory framework, which is based on sound financial calculations and the results of experiments. In France, no one demands the adoption of an appropriate regulatory framework, and lobbyists from Canada, the UK, Holland, and Israel are not trying to impose conditions for the adoption of bills that limit the possibilities of French hemp breeders. Unfortunately, in our country, everything is exactly the opposite. Around the bill there is a lot of noise and lies (for example, state structures in France have calculated that the number of patients requiring hemp therapy can reach 200 thousand people - in Ukraine they appeal with unreasonable figures of 2-2.5 million). At the moment, no one offers financial justification for the need to adopt an appropriate regulatory framework and even more so does not say that it is necessary to study this issue in detail in the course of well-prepared and conducted experiments. Including appealing to the emotions of the Ukrainian public, and not to cold calculation and competent justification, ignoring the interests of national hemp growers, as well as effective developments that allow the use of therapeutic therapeutic hemp leaves and inflorescences for industrial purposes, speak of the use of Ukrainian citizens in adopting legislation lobbying foreign companies primarily in their interests. 

In particular, it depends on the Ukrainian public whether we will follow the scenario in this matter already implemented in Latin American countries where there is an unprecedented dominance of international hemp companies, mainly headquartered in Canada, or we will do as this policy is implemented in Holland, Israel, Uruguay , Australia, Great Britain, USA - when the conditions created by government officials allow the national producer to develop and he in an extremely short time not only fills the domestic market with high-quality and cheap products, but also creates capacities for the export of hemp raw materials or final products with high added value.

Как законно использовать цветы конопли
14.10.2020

 

Объявления
Все объявления »
 
 

facebook

telegram

twitter